|
|||||
|
|
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis |
|
| Authors: | Niklas Bergvall Allison A Petrilla Swapna U Karkare Raquel Lahoz Neetu Agashivala Ashish Pradhan |
| Institution: | 1. Novartis Pharma AG BaselSwitzerland;2. IMS Health Plymouth Meeting, PAUSA;3. Novartis Pharmaceuticals Corporation East Hanover, NJUSA |
| Abstract: | |
| Keywords: | Multiple sclerosis Persistence Adherence Fingolimod Interferon Glatiramer acetate Natalizumab |